FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPF	ROVAL				
OMB Number:	3235-0287				
Estimated average burden					
hours per response	e 0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

mstru	ction 1(b).						•								
<u> </u>	pe Response		*	2.1	> T		. T	T. 1	0 1 1		Palational	in of Pone	ting Dorgan(s) t	a Iomes	
1. Name and Address of Reporting Person – STEER RANDOLPH C				2. Issuer Name and Ticker or Trading Symbol TECHNE CORP /MN/ [tech]									ting Person(s) to k all applicable	:)	
(Last) (First) (Middle) C/O BIOCRYST PHARMACEUTICALS, INC, 2190 PKWY LAKE DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 10/23/2003							XDirector10% Owner Officer (give title below) Other (specify below)					
(Street) BIRMINGHAM, AL 35244				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	S. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(Cit		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if Code (Instr. 8) (Instr. 3, 4 and 5) (Month/Day/Year) (A) or Disposed of (D) (Instr. 3, 4 and 5)		uired 5. A of (D) Ow Tra	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) Ownership of Indirect Beneficial Ownership Or Indirect Ownership or Indirect (I)								
ļ				<u> </u>				de v 711	nount (D)	Titee			(II	130. 4)	
Reminder:	Report on a	separate line for each	th class of securitie	s beneficia	ally	owned	direct		ly. s who respoi	nd to the	collectio	n of inform	nation	SEC 1/2	74 (9-02)
								contain		m are no	t require	d to respo	nd unless the		74 (9-02)
									sed of, or Ben		wned				
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Nu		6. Date Exer		7. Title a	nd	8. Price of	9. Number of	10.	11. Nature
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year	Code		of Deriva Securi Acqui (A) or Dispo of (D) (Instr. and 5)	ities ired sed 3, 4,	Expiration D (Month/Day		Amount of		Derivative Security (Instr. 5) Beneficially Owned Following Reported Transaction((Instr. 4)		Form of Derivative Security: Direct (D) or Indirect	of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
director stock option	\$ 32.90	10/23/2003		A		5,000)	10/23/2003	3 10/23/2013	common	5,000	\$ 0	5,000	D	
director stock option	\$ 20							10/21/1999	10/21/2009	common	20,000		20,000	D	
director stock option	\$ 52.6565							11/09/2000	11/09/2010	common	10,000		10,000	D	
director stock option	\$ 29.10							10/18/200	10/18/2011	common	5,000		5,000	D	
director stock option	\$ 30.65							10/24/2002	2 10/24/2012	common	5,000		5,000	D	

Reporting Owners

Reporting Owner Name / Address		Relationships						
		10% Owner	Officer	Other				
STEER RANDOLPH C C/O BIOCRYST PHARMACEUTICALS, INC 2190 PKWY LAKE DRIVE BIRMINGHAM, AL 35244	X							

Signatures

Randolph C. Steer	10/27/2003
**Signature of Reporting	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.